"good chance a higher court will reverse it" I agree. There's nothing "obvious" about what the problem was, and MYGN put a great deal of effort into discovery, research, analysis, and invention. Admiitedly, the BRCA1/2 mutations only affect a small subset of breast cancer patients, which is why health insurance companies are reluctant to cover it unless there is a strong family history of breast or ovarian cancer in a particular family.
Given that women with this family trait had been making serious decisions about whether to ever have children, or decide to have mastectomies and hysterectomies as prophylactic measures on the chance that they had a mutation that was a problem, it's hard to argue that it was trivial or obvious.
In addition, the genes involved are fairly large and there are multiple places where a single base change can cause a problem, so it was never a simple or obvious diagnosis.
News 
Market Data 
Discover 
